Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

From Fortune 500 firms to startups, Crain's exclusive list reveals the Chicago-area companies inventing new ways of doing ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

WisdomTree US Quality Dividend Growth (DGRW), and the iShares Core Dividend Growth (DGRO) are some of the most popular ...